SequelSEC

VITASPRING BIOMEDICAL CO. LTD. VSBC

Services-Commercial Physical & Biological Research · CIK 0001697884 · Fiscal year ends 0131

Revenue
$0
Fiscal year ended 2026-04-30
Operating income
-$392.11K
Fiscal year ended 2026-04-30
Free cash flow
Unavailable
Fiscal year ended 2026-04-30

VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported revenue of $0 and net income of -$410.67K for the fiscal year ended 2026-04-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from VITASPRING BIOMEDICAL CO. LTD.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.

Income

VITASPRING BIOMEDICAL CO. LTD. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-30
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$392.11K
Net income-$410.67K
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$392.11K
Income tax expense$18.56K
Diluted EPSUnavailable
Selling, general & administrative$392.11K
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

VITASPRING BIOMEDICAL CO. LTD. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-30
Cash & equivalentsUnavailable
Total assets$11.43K
Current assets$9.77K
Total liabilities$4.52M
Current liabilities$4.52M
Total equity incl. NCI-$4.51M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

VITASPRING BIOMEDICAL CO. LTD. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-30
Operating cash flow$4.18K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$3.98K
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

VITASPRING BIOMEDICAL CO. LTD. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.00x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VSBC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-06-17View SEC filing
10-Q · Filed 2026-06-17View SEC filing
10-K · Filed 2026-06-17View SEC filing
10-Q · Filed 2026-06-17View SEC filing
10-Q · Filed 2026-06-15View SEC filing
10-K · Filed 2026-06-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.